Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07257614Not Yet Recruiting

Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study

Role: collaborator

NCT05598489Unknown

Development of Novel Fecal Microbial Biomarkers for Inflammatory Bowel Disease

Role: collaborator

NCT04076228Completed

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

Role: lead

NCT03989297Completed

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Role: lead

NCT03454919Phase 2Unknown

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Role: collaborator

All 5 trials loaded